The exploratory analysis for the efficacy and safety of Rikkunshito for appetite loss during the treatment with PEG-interferon and ribavirin

The exploratory analysis for the efficacy and safety of Rikkunshito for appetite loss during the treatment with PEG-interferon and ribavirin - The analysis for the efficacy and safety of Rikkunshito for appetite loss during the treatment with PEG-IFN and ribavirin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001924

Enrollment

Registered

2009-05-01

Start date

2008-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patients with appetite loss during the treatment with PEG-interferon and ribavirin in the patients with hepatitis C

Interventions

Rikkumshito 7.5g per day before meal 2 weeks Domperidone 30mg per day before meal 2 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with appetite loss during the treatment with PEG-IFN+ribavirin

Exclusion criteria

Exclusion criteria: The patients (1)after removal of their stomach (2)with heart failure or severe inflammation (3)with disorder in liver, gallbladder, or pancreas (4)with pregnancy, or breast-feeding now (5)with astrointestinal bleeding, mechanical ileus, perforation in gastrointestine (6)taking prohibited drug during trial (7) impossible to take a drug per oral (8)taking herbal medicine during trial (9)who are unsuitable judged by the responsible person

Design outcomes

Primary

Measure	Time frame
The improvement of appetite loss at 1 and 2 weeks after drug administartion	—

Secondary

Measure	Time frame
The change of the level in the hormone related to appetite at 1 and 2 weeks after drug administartion	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026